PolyPid is a clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary Polymer-Lipid Encapsulation matrix (PLEX) technology. Co.'s product candidates are designed to address diseases with unmet medical needs by pairing its PLEX technology with drugs already approved by the U.S. Food and Drug Administration. Co.'s PLEX technology is designed to deliver drugs directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. Co.'s primary product candidate, D-PLEX100, is for abdominal (soft) tissue. The PYPD average annual return since 2020 is shown above.
The Average Annual Return on the PYPD average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PYPD average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PYPD average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|